Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Marc P BonacaMichael SzarekE Sebastian DebusMark R NehlerManesh R PatelSonia S AnandEva MuehlhoferScott D BerkowitzLloyd P HaskellRupert M BauersachsPublished in: Clinical cardiology (2022)
The combination of rivaroxaban and aspirin significantly reduces ischemic outcomes in patients with PAD after LER. Although no formal head-to-head comparison exists, in a similar population and for similar outcomes, this regimen demonstrated benefit where trials of DAPT were neutral. These data suggest that factor Xa inhibition may provide specific benefits in this population and that DAPT should not be considered a proven substitution.
Keyphrases
- antiplatelet therapy
- venous thromboembolism
- atrial fibrillation
- pulmonary embolism
- minimally invasive
- optic nerve
- low dose
- acute coronary syndrome
- big data
- coronary artery bypass
- randomized controlled trial
- type diabetes
- metabolic syndrome
- ischemia reperfusion injury
- machine learning
- coronary artery disease
- cardiovascular disease
- double blind
- artificial intelligence
- brain injury
- blood brain barrier
- weight loss
- optical coherence tomography
- surgical site infection
- data analysis
- study protocol
- open label